Cargando…
Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma
The treatment of metastatic melanoma has evolved from an era where interferon and chemotherapy were the mainstay of treatments to an era where immunotherapy has become the frontline. Ipilimumab (IgG1 CTLA-4 inhibitor), nivolumab (IgG4 PD-1 inhibitor), pembrolizumab (IgG4 PD-1 inhibitor) and nivoluma...
Autores principales: | Babiker, Hani M, Riaz, Irbaz Bin, Husnain, Muhammad, Borad, Mitesh J |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5308590/ https://www.ncbi.nlm.nih.gov/pubmed/28224120 http://dx.doi.org/10.2147/OV.S100072 |
Ejemplares similares
-
Oncolytic virotherapy including Rigvir and standard therapies in malignant melanoma [Corrigendum]
por: Babiker, HM, et al.
Publicado: (2019) -
Genome Sequences of RIGVIR Oncolytic Virotherapy Virus and Five Other Echovirus 7 Isolates
por: Hietanen, Eero, et al.
Publicado: (2018) -
Cytolytic Properties and Genome Analysis of Rigvir(®) Oncolytic Virotherapy Virus and Other Echovirus 7 Isolates
por: Hietanen, Eero, et al.
Publicado: (2022) -
Adapted ECHO-7 virus Rigvir immunotherapy (oncolytic virotherapy) prolongs survival in melanoma patients after surgical excision of the tumour in a retrospective study
por: Doniņa, Simona, et al.
Publicado: (2015) -
Oncolytic virotherapy in upper gastrointestinal tract cancers
por: Yokoda, Raquel, et al.
Publicado: (2018)